Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors"

Affiliations

¹ Department of Medicine, Division of Infectious Disease, University of Connecticut Health Center, Farmington, Connecticut.
² Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: grant@uchc.edu.

Comment

Lisa Chirch et al. J Am Acad Dermatol. 2015 Apr.

. 2015 Apr;72(4):743.

doi: 10.1016/j.jaad.2014.08.055.

¹ Department of Medicine, Division of Infectious Disease, University of Connecticut Health Center, Farmington, Connecticut.
² Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: grant@uchc.edu.

No abstract available

Comment on

Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part I. Risks associated with tumor necrosis factor-alfa antagonists.
Chirch LM, Cataline PR, Dieckhaus KD, Grant-Kels JM. Chirch LM, et al. J Am Acad Dermatol. 2014 Jul;71(1):1.e1-8; quiz 1.e8-9, 10. doi: 10.1016/j.jaad.2014.01.875. J Am Acad Dermatol. 2014. PMID: 24947698
Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part II. Screening for patients on tumor necrosis factor-alfa antagonists.
Chirch LM, Cataline PR, Dieckhaus KD, Grant-Kels JM. Chirch LM, et al. J Am Acad Dermatol. 2014 Jul;71(1):11.e1-7; quiz 18-20. doi: 10.1016/j.jaad.2014.01.879. J Am Acad Dermatol. 2014. PMID: 24947699
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors.
Duncan KO. Duncan KO. J Am Acad Dermatol. 2015 Apr;72(4):741-3. doi: 10.1016/j.jaad.2014.07.065. J Am Acad Dermatol. 2015. PMID: 25773420 No abstract available.